NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

According to Benzinga Pro, GSK's peer group average for short interest as a percentage of float is 4.22%, which means the company has less short interest than most of its peers. Did you know that ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...

Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

Key TakeawaysBlujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial ...

SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted rapidly in vivo to SPR719, the ...

Blujepa is the first new type of oral antibiotic to treat UTIs to gain approval in more than 20 years. Its development was ...

GSK shared in back in October 2024 that depemokimab reduced nasal polyps in the ANCHOR trials, improving the total endoscopic nasal polyp score at 52 weeks as well as the mean nasal obstruction ...

PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new ...

23andme says it owns the aggregated genetic data of its customers, meaning it can sell it to the highest bidder ...

GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February ...